The role of complement in tumor immune tolerance and drug resistance: a double-edged sword
Authors:
Open Access
- 31 January 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1529184
Abstract
The domain of cancer treatment has persistently been confronted with significant challenges, including those associated with recurrence and drug resistance. The complement system, which serves as the foundation of the innate immune system, exhibits intricate and nuanced dual characteristics in the evolution of tumors. On the one hand, the complement system has the capacity to directly inhibit cancer cell proliferation via specific pathways, thereby exerting a beneficial anti-tumor effect. Conversely, the complement system can also facilitate the establishment of an immune escape barrier for cancer cells through non-complement-mediated mechanisms, thereby protecting them from eradication. Concurrently, the complement system can also be implicated in the emergence of drug resistance through a multitude of complex mechanisms, directly or indirectly reducing the efficacy of therapeutic interventions and facilitating the progression of cancer. This paper analyses the role of the complement system in tumors and reviews recent research advances in the mechanisms of tumor immune tolerance and drug resistance.Keywords
This publication has 116 references indexed in Scilit:
- Therapeutic antibodies in oncology: an immunopharmacological overviewCancer Immunology, Immunotherapy, 2024
- Intracellular Complement (Complosome) is Expressed in Several Types of Human Adult Bone Marrow—Derived Stem CellsStem Cell Reviews and Reports, 2023
- ComplementArthritis & Rheumatology, 2023
- Mild Hypothermia Alleviates Complement C5a-Induced Neuronal Autophagy During Brain Ischemia–Reperfusion Injury After Cardiac ArrestCellular and Molecular Neurobiology, 2022
- Damage-associated molecular patterns in traumaEuropean Journal of Trauma and Emergency Surgery, 2019
- Complement anaphylatoxins as immune regulators in cancerCancer Medicine, 2014
- Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancerImmunologic Research, 2012
- Membrane attack by complement: the assembly and biology of terminal complement complexesImmunologic Research, 2011
- HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9Basic Research in Cardiology, 2003
- The membrane attack complex of complement induces caspase activation and apoptosisEuropean Journal of Immunology, 2002